1. Safe eradication of large established tumors using neovasculature‐targeted tumor necrosis factor‐based therapies
- Author
-
Bart Vandekerckhove, Anje Cauwels, Gilles Uzé, An Goethals, Stijn De Munter, Nele Vanderroost, Alexander Van Parys, Frank Peelman, Jan Tavernier, Jennyfer Bultinck, Peter Brouckaert, Annick Verhee, Jeroen Hostens, Leander Huyghe, Sandra Van Lint, Niko Kley, Lennart Zabeau, Universiteit Gent = Ghent University [Belgium] (UGENT), Department for Molecular Biomedical Research, Dynamique des interactions membranaires normales et pathologiques (DIMNP), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Department of Medical Protein Research, and VIB
- Subjects
Lipopolysaccharides ,0301 basic medicine ,Medicine (General) ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,TNF ,QH426-470 ,neovasculature ,Targeted therapy ,0302 clinical medicine ,Interferon ,AMINOPEPTIDASE N ,Medicine and Health Sciences ,IFN-GAMMA ,FACTOR-ALPHA ,Articles ,targeted therapy ,3. Good health ,interferons ,Toxicity ,Cytokines ,Molecular Medicine ,Tumor necrosis factor alpha ,Immunotherapy ,medicine.drug ,INTERFERON ,EXPRESSION ,Combination therapy ,tumor necrosis factor ,Immunology ,tumor necrosis ,Article ,Interferon-gamma ,03 medical and health sciences ,Therapeutic index ,R5-920 ,Downregulation and upregulation ,In vivo ,Chemical Biology ,medicine ,Genetics ,cancer ,Pharmacology & Drug Discovery ,COMBINATION ,RECEPTOR ,Tumor Necrosis Factor-alpha ,business.industry ,FACTOR ,Biology and Life Sciences ,ISOLATED LIMB PERFUSION ,ENDOTHELIAL-CELLS ,030104 developmental biology ,Cancer research ,business ,030217 neurology & neurosurgery - Abstract
Systemic toxicities have severely limited the clinical application of tumor necrosis factor (TNF) as an anticancer agent. Activity‐on‐Target cytokines (AcTakines) are a novel class of immunocytokines with improved therapeutic index. A TNF‐based AcTakine targeted to CD13 enables selective activation of the tumor neovasculature without any detectable toxicity in vivo. Upregulation of adhesion markers supports enhanced T‐cell infiltration leading to control or elimination of solid tumors by, respectively, CAR T cells or a combination therapy with CD8‐targeted type I interferon AcTakine. Co‐treatment with a CD13‐targeted type II interferon AcTakine leads to very rapid destruction of the tumor neovasculature and complete regression of large, established tumors. As no tumor markers are needed, safe and efficacious elimination of a broad range of tumor types becomes feasible., TNF and IFN‐γ are cytokines with great anticancer potential but with limited clinical application due to side‐effects. In the present study, the tumor endothelium is identified as target cell for their antitumor activity and new biologics that allow their safe targeting are developed.
- Published
- 2020